GCG and type 2 diabetes mellitus: Tirzepatide, a novel dual agonist for both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors,5 has demonstrated excellent glucose-lowering effects in preclinical studies and has been used to improve glycemic control in patients with type 2 diabetes.6, 7, 8, 9, 10 Tirzepatide is also under review for chronic weight management.